Clinical Trial

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-10; most recent amendment 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2025-09-08
Trial Details
NCT Number NCT06933056
Lead Sponsor University of Michigan
Collaborators: Lexicon Pharmaceuticals
Conditions Platelet Function and Reactivity Tests
Enrollment 20 participants
Start Date 2025-09-02
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-15